ALBO stock information

Sector:

Healthcare

Description:

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

Albireo Pharma, Inc. website

Current Price

$44.15

RSI

52.66

Market Capitalization:

613.2M

Beta:

1.105

Volume:

1,241,282

Analyst Target Price:

$ 73.4

Economiic Fair Price:

Earnings DateNovember 03, 2022

Report DateNovember 08, 2022

QuarterQ3

Forward Dividend N/A

Forward Dividend Rate N/A

Dividend N/A

Dividend Rate N/A

Payout Ratio N/A

Cash222.5M

Debt

EPS-1.77

Profit Margin-83.90 %

Revenue Per Share TTM2.111

Return On Equity TTM-0.191

YoY Revenue Growth (TTM)

437.80 %

YoY Pre Tax Income Growth (TTM)

-32.07 %

YoY Free Cash Flow (TTM)

-59.70 %

QoQ Revenue Growth

168.34 %

QoQ Pre Tax Income Growth

-162.09 %

QoQ Free Cash Flow Growth

-270.06 %

2021 Revenue

$ 40.6M

388.43 %

2020 Revenue

$ 8.3M

-13.78 %

2019 Revenue

$ 9.6M

-24.36 %

2018 Revenue

$ 12.7M

1273900.00 %

2017 Revenue

$ 1K

-99.99 %

2016 Revenue

$ 11.4M

2021 Free Cash Flow

$ -108M

-6.84 %

2020 Free Cash Flow

$ -101.1M

-89.13 %

2019 Free Cash Flow

$ -53.5M

-99.01 %

2018 Free Cash Flow

$ -26.9M

3.22 %

2017 Free Cash Flow

$ -27.8M

-215.88 %

2016 Free Cash Flow

$ -8.8M

2021 Pre Tax Income

$ -34M

68.38 %

2020 Pre Tax Income

$ -107.6M

-71.62 %

2019 Pre Tax Income

$ -62.7M

-36.07 %

2018 Pre Tax Income

$ -46.1M

-90.44 %

2017 Pre Tax Income

$ -24.2M

-48.59 %

2016 Pre Tax Income

$ -16.3M

Albireo Pharma, Inc.(ALBO)